InSite's AzaSite royalties from Merck help avoid debt default
This article was originally published in Scrip
InSite Vision has renegotiated its licence agreement with Merck & Co so that the Alameda, California-based company receives minimum royalty payments for AzaSite (azithromycin ophthalmic solution) 1% from its big pharma partner on a quarterly rather than yearly basis to avoid defaulting on its $60 million debt secured by AzaSite royalties.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.